title: Neuroleptic malignant syndrome.
authors.affiliation: University of Cincinnati, Department of Psychiatry, College of Medicine, Box 670559, Cincinnati, OH 45267-0559, USA. strawnjr@uc.edu
authors.forename: Jeffrey R
authors.initials: JR
authors.lastname: Strawn
authors.forename: Paul E
authors.initials: PE
authors.lastname: Keck
authors.forename: Stanley N
authors.initials: SN
authors.lastname: Caroff
mesh_terms: D000328:Adult; D000547:Amantadine; D000978:Antiparkinson Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001569:Benzodiazepines / Q000627:therapeutic use; D001971:Bromocriptine / Q000627:therapeutic use; D003620:Dantrolene / Q000627:therapeutic use; D003937:Diagnosis, Differential; D004298:Dopamine / Q000502:physiology; D004565:Electroconvulsive Therapy; D005260:Female; D006801:Humans; D008140:Lorazepam / Q000627:therapeutic use; D009125:Muscle Relaxants, Central / Q000627:therapeutic use; D009459:Neuroleptic Malignant Syndrome / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology; D012307:Risk Factors
chemical_list: D000978:Antiparkinson Agents; D014150:Antipsychotic Agents; D009125:Muscle Relaxants, Central; D001569:Benzodiazepines; D001971:Bromocriptine; D000547:Amantadine; D003620:Dantrolene; D008140:Lorazepam; D004298:Dopamine